Senior Manager, R&D Finance
BeiGene
Summary
BeOne Medicines is seeking a strategic R&D finance partner to join our R&D Finance team. Reporting to the Executive Director, R&D Finance, this role will lead and execute key R&D financial planning, monthly close, consolidation, and executive reporting. Additionally, the individual will evaluate pipeline investments and provide strategic decision analysis for project transitions. The ideal candidate brings deep FP&A and portfolio valuation expertise within the biopharma or life sciences sector, a solid grasp of R&D processes, and a proven ability to partner across global R&D, Finance, and executive leadership.
Job description
Financial Planning & Consolidation
- Lead quarterly forecasting and monthly reporting processes: Consolidate functional and program R&D submissions to deliver accurate roll-ups, clear variance commentary, and timely leadership updates.
- Prepare executive-ready reporting packages, budget-versus-actual analyses, and risk/opportunity summaries for management reviews.
- Support global R&D planning, budgeting, and long-range planning.
Strategic Portfolio & Valuation Support
- Conduct sophisticated financial analysis and pipeline valuations to inform R&D investments.
- Partner cross-functionally with R&D, Commercial, Finance, and other departments to deliver scenario modeling and financial insights for governance forums.
Process Improvement & Operations
- Maintain and enhance financial models, reporting dashboards, and tracking templates to improve visibility across R&D spend.
- Drive process efficiency by implementing reporting automation, standardized workflows, and modern financial technologies.
Requirements
- Bachelor's degree in Finance, Accounting, Economics, Life Sciences, or related field
- 7+ years of overall experience
- 6+ years of progressive FP&A or finance experience in biotechnology, pharmaceuticals, or life sciences
- Majority of experience supporting a global R&D function
- Demonstrated experience managing R&D or clinical development budgets, monthly closes, and global financial consolidations
- Strong experience leading and/or supporting core FP&A processes, including budgeting, forecasting, variance analysis, and long-range financial planning
- Strong background in pipeline valuation, portfolio analytics, scenario modeling, and risk-adjusted decision frameworks
- Proven capability to translate complex scientific and financial data into clear, actionable executive insights
- Excellent communication and influencing skills, with a track record of building trusted cross-functional partnerships
- Strong project management abilities, high accountability, sound business judgment, and a continuous-improvement mindset
- Demonstrated experience in leveraging AI/Automation tools to gain efficiency
- Advanced Excel and PowerPoint skills
- Hands-on experience with enterprise tools (e.g., SAP, TM1, Anaplan, Hyperion, Power BI, Tableau)
Benefits
- Medical, Dental & Vision
- 401(k)
- FSA/HSA
- Life Insurance
- Paid Time Off
- Wellness
- Annual Bonus Plan
- Discretionary Equity Awards
- Employee Stock Purchase Plan
Company overview
BeiGene, Ltd., now rebranding as BeOne Medicines, is a global commercial-stage biotechnology company specializing in the discovery, development, manufacturing, and commercialization of innovative oncology medicines. Founded in 2010 by John V. Oyler and Xiaodong Wang, the company has grown into a multinational organization with headquarters in Cambridge, Massachusetts, Beijing, China, and Basel, Switzerland. BeiGene focuses on developing targeted and immune-oncology therapies for cancer treatment, with a diverse pipeline that includes internally discovered products like BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor, and Tevimbra (tislelizumab), a PD-1 inhibitor. The company operates across six continents with over 45 countries participating in clinical trials and has enrolled more than 30,000 patients in its research programs. With approximately 12,000 employees worldwide, BeiGene has established itself as a significant player in global oncology, particularly with strong market presence in China and expanding operations in the United States and Europe. The company's mission centers on expanding access to high-quality cancer therapies worldwide through persistent innovation and challenging traditional approaches to drug development.